Patidegib hydrochloride is under clinical development by Sol-Gel Technologies and currently in Phase III for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome). According to GlobalData, Phase III drugs for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Patidegib hydrochloride LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Patidegib hydrochloride overview
Patidegib is under development for the treatment of Gorlin syndrome. The drug candidate is administered orally and applied topically. It acts by targeting smoothened homolog. It was under development for the treatment of advanced and/or metastatic solid tumor malignancies and pancreatic cancer. It was also under development for the treatment of myelofibrosis and metastatic or locally advanced (unresectable) chondrosarcoma, basal cell carcinomas.
See Also:
Sol-Gel Technologies overview
Sol-Gel Technologies (Sol-Gel) is a dermatology company that carries out the identification, development and commercialization of investigational and generic topical drug products for the treatment of skin diseases. The company provides products under the brand name EPSOLAY for the treatment of inflammatory lesions of rosacea in adults and TWYNEO for the treatment of acne vulgaris. It also offers SGT-210, SGT-310 and SGT-510 drug candidates to treat plaque psoriasis and other dermatologic indications. Sol-Gel utilizes silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs. It operates in the US and Israel. Sol-Gel is headquartered in Ness Ziona, Israel.
For a complete picture of Patidegib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
